"label","text","id","instanceType","uuid:ID","name","description"
"","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","Objective_1","Objective","a98580a4-518c-47f6-bc08-1b157bd4e04c","OBJ1","Main objective"
"","To document the safety profile of the xanomeline TTS.","Objective_2","Objective","c50d72a8-3090-4af8-a6a5-c674610822ce","OBJ2","Safety"
"","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","Objective_3","Objective","48373d25-1e22-44a1-a8e3-bb2ec68a7496","OBJ3","Behaviour"
"","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","Objective_4","Objective","81fb96ed-8e93-4e13-8d29-e8cd3e2aa4e1","OBJ4",""
"","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","Objective_5","Objective","2eaac407-e01c-457a-b218-d75a1bc9ca65","OBJ5",""
"","To assess the treatment response as a function of Apo E genotype.","Objective_6","Objective","baf9d1b6-94ac-47f9-b05e-8e125e93d104","OBJ6",""
